Research programme: omega 3 fatty acids therapeutics - AstraZeneca/Ligand Pharmaceuticals

Drug Profile

Research programme: omega 3 fatty acids therapeutics - AstraZeneca/Ligand Pharmaceuticals

Alternative Names: LTP-O3FA

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer AstraZeneca; Ligand Pharmaceuticals
  • Class Anti-inflammatories; Antihyperlipidaemics; Omega 3 fatty acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation; Metabolic disorders
  • No development reported Dyslipidaemias

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for research development in Dyslipidaemias in USA
  • 06 Apr 2018 Preclinical trials in Inflammation in USA (unspecified route) (Ligand Pharmaceuticals pipeline, April 2018)
  • 06 Apr 2018 Preclinical trials in Metabolic disorders in USA (unspecified route) (Ligand Pharmaceuticals pipeline, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top